NCT00668343已完成3 期
Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- attack number
研究概览
简要总结
Patient with relapsing remitting multiple sclerosis taking avonex are included in this double blind randomized control trial. Simvastatin is compared to placebo. end points of edss , total attack, new enhancing lesion and newt2 lesion in mri is evaluated as end point.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 15 Years 至 60 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •>=1 attack in last year
排除标准
- •>2 attacks in study
- •drug complication
研究组 & 干预措施
1
Active Comparator
干预措施: simvastatin (Drug)
2
Placebo Comparator
干预措施: placebo (Drug)
结局指标
主要结局
attack number
时间窗: 1 year
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)Multiple SclerosisNCT01212094National Institute of Neurological Disorders and Stroke (NINDS)44
Unknown
2 期
A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple SclerosisMultiple SclerosisNCT00217295Multiple Sclerosis Institute30
已完成
3 期
Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple SclerosisRelapsing-remitting Multiple SclerosisNCT00200655Nantes University Hospital40
已完成
2 期
Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1bRelapsing-remitting Multiple SclerosisNCT01111656Insel Gruppe AG, University Hospital Bern28
已完成
不适用
Avonex 15 Year Long Term Follow-up StudyMultiple SclerosisNCT00525343Biogen122